Concurrent total hip and knee replacements in a patient with haemophilia with inhibitors using recombinant factor VIIa by continuous infusion

Haemophilia

Volumn 9, Issue 6, 2003, Pages 738-740

  Tagariello, G ^a   Bisson, R ^b   Radossi, P ^a   Petris, U ^b   Zanardo, G ^c   De Biasi, E ^a   Risato, R ^a   Polese, F ^a   Davoli, P G ^a  

^a Servizio Trasfusionale   (Italy)

^b Castelfranco Veneto Hospital   (Italy)

^c Castelfranco Veneto Hospital   (Italy)

Author keywords

FVIIa; Haemophilia; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; TRANEXAMIC ACID;

ADULT; ARTICLE; BOLUS INJECTION; CASE REPORT; CONTINUOUS INFUSION; DRUG COST; DRUG HALF LIFE; DRUG USE; ELECTIVE SURGERY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HIP ARTHROPLASTY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KNEE ARTHROPLASTY; MALE; METHODOLOGY; PRIORITY JOURNAL; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 0347588509     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-8216.2003.00820.x     Document Type: Article

References (13)

1. Herdner U, Blazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 19: 1193.
2. Scharrer I. Recombinant FVIIa for patients with inhibitors to FVIII or IX or FVII deficiency. Haemophilia 1999; 5: 253-9.
3. Tagariello G, De Biasi E, Gajo GB et al. Recombinant FVIIa (NovoSeven) and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: expqience of two cases. Haemophilia 2000; 6: 581-3.
4. Tagariello G, Radossi P, DeBiasi E, Risato R, Davoli PG. Flexibility of recombinant FVIIa continuous infusion in patients with haemophilia and inhibitors. Haemophilia 2002; 8: 576 (abstract).
5. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
6. Goudemand J, Marey A, Renom P et al. Two cases of total hip replacement performed under treatment with recombinant factor VIIa. Haemophilia 1998; 4: 240 (abstract).
7. Mausen-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, Levi M, Peerlink K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998; 53: 249-55.
8. Schulman S, Bech Jensen M, Varon D et al. Feasibility of using recombinant FVIIa in continuous infusion. Thromb Haemost 1996; 75: 432-36.
9. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4: 564-7.
10. Schulman S, d'Oiron R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S97-101.
11. Arnold WD, Hilgartner MW. Hemophilic arthropathy: current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
12. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
13. Smith MP, Ludlam CA, Collins PW et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53.